BioventusvsMerck & Company

BVS and MRK stock compared: price, dividend, valuation and results, from SEC filings.

BVS

Bioventus Inc.

$10.66

Value $710M

-1.84%
BVS's page

MRK

Merck & Company, Inc.

$147.76

Value $365B

+0.55%
MRK's page

Bioventus (BVS) has a market value of $710M and Merck & Company (MRK) $365B. Over the last year, with dividends, BVS moved +39.3% and MRK +66.3%. Dividend yield: BVS none, MRK 2.30%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    BVS$710M

    MRK$365B

    MRK is 514 times BVS

  • Revenue, 12 months

    BVS$586M

    MRK$67.4B

    MRK is 115 times BVS

  • Net income, 12 months

    BVS$57M

    MRK$2.5B

    MRK is 43 times BVS

  • Operating margin

    BVS9.7%

    MRK–

  • ROIC

    BVS9.4%

    MRK3.9%

    5.5 points apart

  • P/E

    BVS–

    MRK148.9

  • Dividend yield

    BVS0.0%

    MRK2.3%

    2.3 points apart

  • 5-year return

    BVS-32.7%

    MRK+104.9%

    137.6 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

BVS-32.7%

MRK+104.9%

010020020222023202420252026
Returns by period
PeriodBVSWith dividendsMRKWith dividends
1 year since November 12, 2025+39.3%Price +39.3%+66.3%Price +61.6%
3 years since November 13, 2023+188.1%+42.3% a yearPrice +188.1%+58.0%+16.5% a yearPrice +44.2%
5 years since November 12, 2021-32.7%-7.6% a yearPrice -32.7%+104.9%+15.4% a yearPrice +75.9%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

BVSBioventusMRKMerck & Company

Valuation

BVSMRK
Valuation
Price$10.66$147.76
Market value$710M$365B
Enterprise value (EV)$918M$409B
P/E–148.9
P/E, 5-year median–14.8
P/B3.08.1
EV/EBIT16.286.0
Free cash flow yield12.0%4.0%

Results and growth

BVSMRK
Results and growth
Revenue, 12 months$586M$67.4B
Net income, 12 months$57M$2.5B
Free cash flow, 12 months$85M$14.7B
Earnings per share, 12 months$0.80$0.98
Revenue growth, year on year-0.9%1.3%
Revenue growth a year, past+12.1%over 5 years+9.4%over 5 years
EPS growth a year, past–+21.2%over 5 years

Margins and returns on capital

BVSMRK
Margins and returns on capital
Gross margin68.7%71.8%
Operating margin9.7%–
Net margin9.8%3.6%
ROIC9.4%3.9%
ROE28.4%5.2%

Balance sheet

BVSMRK
Balance sheet
Cash$31M$9.7B
Total debt$244M$53.8B
Net debt / EBITDA2.05.7
Interest cover–2.4×

Dividends and buybacks

BVSMRK
Dividends and buybacks
Dividend yield–2.3%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield–1.4%
Shareholder yield–3.7%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: BVS or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, Bioventus or Merck & Company?

By market value, Merck & Company ($365B) is about 514.4 times Bioventus ($710M), at today's prices.

How did BVS and MRK stock do over the last 5 years?

Since November 12, 2021, BVS's price moved -32.7% and MRK's +75.9%. With dividends: BVS -32.7% (-7.6% a year), MRK +104.9% (+15.4% a year). Past returns do not predict future ones.

Which pays the higher dividend, BVS or MRK?

The dividend yield at today's price is none for Bioventus and 2.30% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

Which has the higher profit margins, Bioventus or Merck & Company?

Over the last twelve months, the net margin was 9.8% for Bioventus and 3.6% for Merck & Company, and the operating margin 9.7% and –. Revenue was $586M and $67.4B.

Which is the better investment, Bioventus or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.